GLP-1 drugs spare bone but trim lean mass

Design

Systematic review and meta-analysis (46 randomised trials, 13 real-world, 1 pharmacovigilance), GRADE

Population

1,250,717 individuals on GLP-1 receptor agonists

Primary outcome

Bone, muscle and joint outcomes

Effect

No bone or joint effect; lean/fat-free mass reduced (standardised mean difference -0.52, 95% CI -0.80 to -0.23)

As GLP-1 receptor agonists spread for diabetes and obesity, rheumatologists are asked what they do to bone, muscle and joints. This large meta-analysis pooled 60 studies (46 randomised trials and real-world data), over 1.2 million people, assessed with GRADE.

There was no measurable effect on bone mineral density or fractures at any site, and no change in osteoarthritis symptoms on the WOMAC pain, function or stiffness scales. The consistent signal was in muscle: lean or fat-free mass fell with GLP-1 receptor agonists (standardised mean difference -0.52, 95% CI -0.80 to -0.23), driven mainly by liraglutide and semaglutide, and robust across sensitivity analyses. The certainty was low, and the loss appeared largely a consequence of weight loss itself.

The practical message is reassurance on bone and joints, and watchfulness on muscle. For older or frailer patients on these drugs, pair treatment with resistance exercise and adequate protein to protect muscle, and recognise that whether the measured lean-mass loss translates into weaker muscle or worse physical function is not yet known.

• Meta-analysis of 60 studies and over 1.2 million people on GLP-1 receptor agonists, GRADE-assessed.
• No effect on bone mineral density or fractures, and no change in WOMAC osteoarthritis scores.
• Lean or fat-free mass fell consistently (standardised mean difference -0.52), mainly with liraglutide and semaglutide.
• The lean-mass loss was low-certainty and largely attributable to weight loss.
• Pair these drugs with resistance exercise and adequate protein in older or frail patients.

Why it matters

It answers a question patients now ask directly, and flags muscle, not bone, as the musculoskeletal issue to monitor on these drugs.

Don't overread it

Certainty was low and the lean-mass reduction largely tracks weight loss; without muscle-function data, it does not establish clinically meaningful weakness.

The statistics, in plain English

A standardised mean difference of about -0.5 is a moderate effect on lean mass, but low certainty and the link to weight loss mean it may reflect expected body-composition change rather than harmful muscle wasting; no study measured actual muscle strength or function.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.